Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.

摘要: Monoclonal antibodies against vascular endothelial growth factor and epidermal receptor in advanced colorectal cancers: present future directions Purpose of review Targeted therapies are emerging as potentially important therapeutic interventions the treatment cancer. There have been considerable developments this field within past few years, with some agents entering clinic others soon to follow. tumorigenic targets development for over a decade. Recently, cetuximab bevacizumab generated significant interest focus review. Recent findings Cetuximab, monoclonal antibody receptor, bevacizumab, factor, now subject rigorous assessment several clinical studies, including large randomized phase II study III bevacizumab. The demonstration efficacy safety these has led issue licenses Switzerland United States. Summary These results rapid expansion further studies define role aid their integration conventional approaches management